care

(redirected from Best Supportive Care)
Also found in: Dictionary, Medical, Legal, Acronyms, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • all
  • verb
  • noun
  • phrase

Synonyms for care

Synonyms for care

a cause of distress or anxiety

careful forethought to avoid harm or risk

the function of watching, guarding, or overseeing

the systematic application of remedies to effect a cure

to have an objection

Synonyms

care for: to have the care and supervision of

Synonyms for care

judiciousness in avoiding harm or danger

an anxious feeling

Synonyms

Related Words

a cause for feeling concern

attention and management implying responsibility for safety

prefer or wish to do something

Synonyms

Related Words

be concerned with

Synonyms

Related Words

References in periodicals archive ?
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
The rates of bleeding complications and infections were similar with best supportive care and risk of infection requiring intravenous antibiotic use was reduced by one-third with VIDAZA compared to conventional care regimens.
Notes to Editor About the REGARD trial REGARD is a global, randomized, double-blind, placebo-controlled Phase III study of ramucirumab and best supportive care compared to placebo and best supportive care as treatment in patients with advanced gastric cancer (including adenocarcinomas of the gastro-esophageal junction) following progression after initial chemotherapy.
Patients in the study will be randomized into two treatment groups: HuMax-EGFr in combination with best supportive care or best supportive care alone.
The IDRC assessed the safety profile of seliciclib and recommended that the study continue after reviewing data from 173 patients with previously-treated non-small cell lung cancer (NSCLC), of whom 45 proceeded into the blinded portion of the study and were randomized to receive either seliciclib or best supportive care.
The MCD2001 study assessed the efficacy and safety of siltuximab plus best supportive care (BSC) compared with placebo plus BSC in patients with MCD.
The approval of Stivarga by the MHLW is based on data from the international multicenter pivotal Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial which evaluated regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with mCRC, whose disease has progressed after approved standard therapies.
Additionally, low-dose Ara-C provided no survival benefit when compared with best supportive care.
The international multicenter Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial evaluated regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with mCRC, whose disease has progressed after approved standard therapies.
The study enrolled 157 patients in Russia and Ukraine who were randomized in a two-to-one ratio to two treatment arms, CRLX101 plus Best Supportive Care (BSC) compared to BSC alone.
COPENHAGEN, Denmark -- Celgene International Sarl (Nasdaq:CELG) today announced that data showed VIDAZA (azacitidine) provides a significant overall survival benefit for patients with higher-risk myelodysplastic syndromes (MDS) regardless of whether patients were treated with low-dose Ara-C or best supportive care in the control arm.
The GRID study evaluated regorafenib plus best supportive care (BSC), versus placebo plus BSC in patients with metastatic and/or unresectable GIST whose disease had progressed despite prior treatment with imatinib and sunitinib.
At this year's congress, Professor Valeria Santini, of the University of Florence, Italy, presented data which showed that azacitidine provided a significant overall survival benefit for patients with higher-risk MDS regardless of whether patients were treated with low-dose Ara-C or best supportive care in the control arm.
The approval of Stivarga in GIST is based on data from the pivotal Phase III GRID (GIST Regorafenib In Progressive Disease) trial, which showed that Stivarga plus best supportive care (BSC) statistically significantly improved progression-free survival (PFS) compared to placebo plus BSC (HR=0.
The Phase III study CORRECT randomized 760 patients with mCRC whose disease had progressed after currently approved standard therapies to receive regorafenib plus best supportive care (BSC) or placebo plus BSC at a 2:1 ratio.